Clinical Trial: Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID

U.S., June 5 -- ClinicalTrials.gov registry received information related to the study (NCT07627815) titled 'Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID' on May 24.

Brief Summary: This will be a six-week, randomized, parallel, two group, open-label design. Patients will be treated with Paragon Novel Metabolic Regulator (PNMR) + standard of care (SOC) or SOC alone for 6 weeks for the treatment of Long COVID. All patients will also be provided with with Dietary & Lifestyle recommendations specifically designed to enhance immune system function and reduce viral proliferation.

Patients will be assessed in the clinic at screening/baseline, 3 and 6 weeks while on treatment, and by telephone at 4 weeks post-treatment. ...